{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:42:03Z","timestamp":1792701723527,"version":"4.5.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T00:00:00Z","timestamp":1436918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0131864","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T14:40:54Z","timestamp":1436971254000},"page":"e0131864","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis"],"prefix":"10.1371","volume":"10","author":[{"given":"Jeong-Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hyoun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Rang","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,7,15]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"JC Davis","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"D van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"D van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER","volume":"8","author":"L Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/acr.20258","article-title":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register","volume":"62","author":"LE Kristensen","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","article-title":"Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"MM Soliman","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"S van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"J Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"E Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"B Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"ref11","first-page":"1010","article-title":"Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients","volume":"29","author":"S Dadoun","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","article-title":"Efficacy in current practice of switching between anti-tumour necrosis factor- alpha agents in spondyloarthropathies","volume":"50","author":"J Paccou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"JJ Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"9\u201310","key":"ref14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","article-title":"Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis","volume":"160","author":"G Haberhauer","year":"2010","journal-title":"Wien Med Wochenschr"},{"issue":"5 Suppl1","key":"ref15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","article-title":"Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles","volume":"34","author":"PJ Anderson","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"14","key":"ref16","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"GM Bartelds","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"TR Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref18","first-page":"1955","article-title":"Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab2012 Dec","author":"C Plasencia","journal-title":"Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab2012 Dec"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/rheumatology\/ker281","article-title":"Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry","volume":"50","author":"N Busquets","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"ref20","first-page":"862","article-title":"Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment","volume":"34","author":"C Lukas","year":"2007","journal-title":"J Rheumatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0131864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T06:30:25Z","timestamp":1540276225000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0131864"}},"subtitle":[],"editor":[{"given":"James T.","family":"Rosenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,7,15]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0131864","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,15]]}}}